Cargando…
Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
BACKGROUND: We studied the use of teriparatide in postmenopausal women with severe osteoporosis. MATERIAL/METHODS: Two groups (A and B) of patients affected by severe osteoporosis (T-score ⩽−2.5 at bone mineral density were analyzed and 2 vertebral fractures on radiograph). Group A was treated for 1...
Autores principales: | Panico, Annalisa, Lupoli, Gelsy Arianna, Marciello, Francesca, Lupoli, Roberta, Cacciapuoti, Marianna, Martinelli, Addolorata, Granieri, Luciana, Iacono, Daniela, Lupoli, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539612/ https://www.ncbi.nlm.nih.gov/pubmed/21804463 http://dx.doi.org/10.12659/MSM.881905 |
Ejemplares similares
-
Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome
por: Panico, Annalisa, et al.
Publicado: (2017) -
Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report
por: Lupoli, Gelsy Arianna, et al.
Publicado: (2019) -
Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
por: Monda, Vincenzo, et al.
Publicado: (2017) -
Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis
por: Qin, Ling, et al.
Publicado: (2007) -
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)